If you don't add the test to your cart on this page use the promotion code above to receive the discounted price.
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: AFP and AFP-L3%, AlphaFetoprotein AFP and AFPL3
Also known as: CA 125 Tumor Marker, CA-125, Cancer Antigen 125, OC125, Ovarian Antigen
Also known as: CA 153, CA-Breast, Cancer Antigen 15-3, Cancer Antigen-Breast
Also known as: CA 199, Carbohydrate Antigen 19-9
Also known as: CA 2729, Cancer Ag 27-29
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Carcinoembryonic Antigen
Also known as: Fecal Globin by Immunochemistry InSure, FOBT, InSure®, Occult Blood, Stool Blood, Stool Hemoglobin
Also known as: Chorionic Gonadotropin, hCG Total Quantitative, Human Chorionic Gonadotropin (Hcg), Quantitative , Human Chorionic Gonadotropin Total, Quantitative
Also known as: Lactate Dehydrogenase LD, LDH
Also known as: Anti-TPO, Antithyroid Antibodies, TgAb, Thyroglobulin Antibodies TgAb, Thyroglobulin Antibody (TgAb), Thyroid Antibodies, Thyroid Autoantibodies, Thyroid Peroxidase Antibody (TPOAb), Thyroid Stimulating Immunoglobulin, Thyroperoxidase Antibody, Thyrotropin Receptor Antibodies, TPOAb, TSH Receptor Antibody, TSI
The CA-3. Cancer Screening - Women panel contains 13 tests with 46 biomarkers.
Brief Description: The CA-3 Cancer Screening - Women panel is an extensive diagnostic tool designed for an in-depth analysis of various cancer-related markers, specifically tailored for women. This advanced screening panel integrates additional markers to enhance the detection and monitoring capabilities for a broad spectrum of cancers. It is instrumental in providing a comprehensive overview of a woman's cancer risk profile, facilitating early intervention, and guiding effective treatment strategies.
Collection Method: Blood Draw and Fecal Collection
Specimen Type: Whole Blood, Serum, and Feces
Test Preparation: 12 Hours Overnight Fasting Required
The CA-3 Cancer Screening - Women panel is typically ordered for women with a high risk of cancer, such as those with a strong family history of cancer, genetic predispositions, or previous cancer diagnoses who require thorough monitoring. It may also be recommended for women experiencing symptoms that suggest possible cancer, including unexplained weight changes, persistent discomfort, or other signs indicative of cancer. This panel is crucial for tracking the effectiveness of ongoing treatments and for monitoring any recurrence or progression of the disease.
This panel includes several tests that play a pivotal role in the detection and management of cancer:
Alpha-Fetoprotein and AFP-L3: Used primarily for liver cancer detection, these markers help differentiate between benign and malignant liver pathologies.
Amylase: Elevated amylase levels can indicate pancreatic cancer, which is crucial for early diagnosis and treatment planning.
CA 125: A key marker for ovarian cancer, helpful in tracking disease progression and response to therapy.
CA 15-3: Primarily used to monitor breast cancer treatment and for detecting recurrence.
CA 19-9: While commonly associated with pancreatic cancer, it is also indicative of other gastrointestinal cancers.
CA 27.29: This marker is used to monitor breast cancer, particularly assessing therapy effectiveness and disease status.
Complete Blood Count with Differential and Platelets: Provides a general health snapshot and can indicate abnormal conditions or effects of cancer treatment.
CEA: A versatile marker, primarily used for colorectal cancer but also for other types of cancer.
Fecal Globin by Immunochemistry: Important for screening for colorectal cancer by detecting blood in the stool.
Gastrin: Elevated levels can indicate issues like Zollinger-Ellison syndrome, which can be associated with tumors.
Total hCG Quantitative: Besides pregnancy detection, it's used to monitor certain types of cancer.
Lactate Dehydrogenase: An indicator of cellular turnover and is often elevated in various cancers.
Thyroglobulin Antibodies: Essential for detecting interference in thyroid cancer markers, particularly useful in monitoring recurrence.
For those seeking the ultimate in comprehensive cancer screening, the CA-4 Cancer Screening - Women panel offers an expanded set of markers. This panel includes all the tests found in CA-3 and adds critical markers such as Calcitonin, for detecting medullary thyroid cancer, and Des-Gamma-Carboxy-Prothrombin for more accurate liver cancer diagnosis. It represents the most detailed and expansive cancer screening available, ideal for high-risk patients or those needing detailed monitoring post-diagnosis.
This panel assists in detecting and monitoring several types of cancers:
Liver Cancer: Markers like Alpha-Fetoprotein and AFP-L3 provide essential diagnostics.
Pancreatic and Gastrointestinal Cancers: Amylase and CA 19-9 levels are critical in identifying these cancers.
Ovarian Cancer: CA 125 is a pivotal tool for monitoring and diagnosing this type of cancer.
Breast Cancer: CA 15-3 and CA 27.29 are utilized for treatment monitoring and recurrence detection.
Colorectal Cancer: Fecal Globin by Immunochemistry is used for early screening, essential for effective treatment.
Healthcare professionals use the CA-3 panel results to:
Tailor Treatments: Based on specific biomarkers, treatments can be personalized to improve efficacy.
Monitor Treatment Response: Regular testing provides insights into how well the cancer responds to the chosen treatment strategy.
Early Detection and Prevention: Identifying cancer at an early stage can significantly improve the prognosis.
The CA-3 Cancer Screening - Women panel is an invaluable tool in the detection and management of cancer, providing essential insights that can lead to early intervention and more tailored treatment approaches. Its comprehensive range of markers allows for a nuanced understanding of a patient's cancer status, making it an indispensable part of cancer care for women at elevated risk or undergoing treatment.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.